ERBB2 and ovarian cancer: In a previous study, co-treatment with Ec1–LoPE and the anti-HER2 monoclonal antibody trastuzumab delayed tumor growth and significantly prolonged survival of mice bearing EpCAM- and HER2-expressing ovarian cancer SKOV3 xenografts compared to single treatments, while no pathological changes in normal organs, e.g., kidneys and livers, were detected [48].